Immunology: A New Frontier in Medical Science

Kutubkhan Bohari | July 16, 2022 | 1256 views | Read Time : 27:22 min

Immunology

Introduction

Recent developments in the bioengineering of monoclonal antibodies (mAbs) have revolutionized the treatment of numerous rheumatic and immunological disorders.

Currently, several immunological disorders are successfully being targeted and treated using innovative medical techniques such as immunotherapy. Leading companies are increasingly investing in research activities to expand the usage and application of immunology for the treatment of various infectious diseases, including multiple sclerosis, inflammatory bowel disorders, lupus, and psoriasis, leading companies are increasingly investing in research activities.

Today, the efforts of researchers in immunology, with a long history of study and research, have borne fruit, as bioengineered mAbs are now being employed in clinical practices.


Accelerating Investments: Paving the Way for Immunology

The increasing prevalence of infectious diseases, cancer, and immune-mediated inflammatory disorders (IMIDs) is raising the need for more precise classification and an in-depth understanding of the pathology underlying these ailments.

Numerous leaders in the biotechnology domain are thus focusing on undertaking numerous strategies, such as new facility launches and collaborations, to address the need by finding deeper inroads into immunology and its use in disease treatments.

For instance, in 2022, the University of Texas MD Anderson Cancer Center announced the launch of a visionary research and innovation hub, the James P. Allison Institute, to find new roads in immunotherapy, develop new treatments, and foster groundbreaking science.

These developments will result in better diagnosis through the use of selective biomarkers, and early detection of fatal diseases and their treatment, which will prevent complications from happening. Also, the identification of high-risk populations through a deeper understanding of genetic and environmental factors can assist in the prevention of disease through immunotherapy. 


The Way Forward

Immunology has led to the development of biotechnology, making it possible to develop novel drugs and vaccines, as well as diagnostic tests, that can be used to prevent, diagnose, and treat a wide range of autoimmune, infectious, and cancerous diseases.

With the rapid advancement in technology and the integration of artificial intelligence, immunology is finding its way into an array of domains and industries, encompassing several research areas including medicine, pharmaceuticals, agriculture, and space.

Today, not only researchers but also leading biotech and pharmaceutical companies have recognized that conventional therapies with pharmaceutical and chemical products are being replaced by products derived from immunology. This is because they work well for health problems, are environmentally friendly, and are also emerging as a wealth-generating business in the medical field.

Spotlight

Cook General Biotechnology

Cook General BioTechnology, LLC (CGBT), was formed after Cook Medical purchased the private company, General BioTechnology, LLC., in the spring of 2012. CGBT is actively involved in cell therapy and has assisted in the development and refinement of advanced cryopreservation and banking procedures for differing cell and tissue types.

OTHER ARTICLES
MedTech

Top 10 biotech IPOs in 2019

Article | July 13, 2022

The big question at the start of 2019 was whether the IPO window would stay open for biotech companies, particularly those seeking to pull off ever-larger IPOs at increasingly earlier stages of development. The short answer is yes—kind of. Here’s the long answer: In the words of Renaissance Capital, the IPO market had “a mostly good year.” The total number of deals fell to 159 from 192 the year before, but technology and healthcare companies were standout performers. The latter—which include biotech, medtech and diagnostics companies—led the pack, making up 43% of all IPOs in 2019. By Renaissance’s count, seven companies went public at valuations exceeding $1 billion, up from five the year before

Read More
MedTech

Cell Out? Lysate-Based Expression an Option for Personalized Meds

Article | July 5, 2022

Cell-free expression (CFE) is the practice of making a protein without using a living cell. In contrast with cell line-based methods, production is achieved using a fluid containing biological components extracted from a cell, i.e., a lysate. CFE offers potential advantages for biopharma according to Philip Probert, PhD, a senior scientist at the Centre for Process Innovation in the U.K.

Read More
MedTech

Closing bacterial genomes from the human gut microbiome using long-read sequencing

Article | September 22, 2022

In our lab, we focus on the impact of the gut microbiome on human health and disease. To evaluate this relationship, it’s important to understand the particular functions that different bacteria have. As bacteria are able to exchange, duplicate, and rearrange their genes in ways that directly affect their phenotypes, complete bacterial genomes assembled directly from human samples are essential to understand the strain variation and potential functions of the bacteria we host. Advances in the microbiome space have allowed for the de novo assembly of microbial genomes directly from metagenomes via short-read sequencing, assembly of reads into contigs, and binning of contigs into putative genome drafts. This is advantageous because it allows us to discover microbes without culturing them, directly from human samples and without reference databases. In the past year, there have been a number of tour de force efforts to broadly characterize the human gut microbiota through the creation of such metagenome-assembled genomes (MAGs)[1–4]. These works have produced hundreds of thousands of microbial genomes that vastly increase our understanding of the human gut. However, challenges in the assembly of short reads has limited our ability to correctly assemble repeated genomic elements and place them into genomic context. Thus, existing MAGs are often fragmented and do not include mobile genetic elements, 16S rRNA sequences, and other elements that are repeated or have high identity within and across bacterial genomes.

Read More

Selexis Cell Line Development Strategies

Article | February 11, 2020

In today’s biotechnology landscape, to be competitive, meet regulations, and achieve market demands, “we must apply Bioprocessing 4.0,” said Igor Fisch, PhD, CEO, Selexis. In fact, in the last decade, “Selexis has evolved from cloning by limiting dilution to automated cell selection to nanofluidic chips and from monoclonality assessment by statistical calculation to proprietary bioinformatic analysis,” he added. Single-use processing systems are an expanding part of the biomanufacturing world; as such, they are a major component of Bioprocessing 4.0. “At Selexis, we use single use throughout our cell line development workflow. Currently, we have incorporated single-use automated bioprocessing systems such as ambr® and the Beacon® optofluidic platform for accelerated cell line development. By using these systems and optimizing our parameters, we were able to achieve high titers in shake flasks. Additionally, the Beacon systems integrate miniaturized cell culture with high-throughput liquid handling automation and cell imaging. This allows us to control, adjust, and monitor programs at the same time,” noted Fisch.

Read More

Spotlight

Cook General Biotechnology

Cook General BioTechnology, LLC (CGBT), was formed after Cook Medical purchased the private company, General BioTechnology, LLC., in the spring of 2012. CGBT is actively involved in cell therapy and has assisted in the development and refinement of advanced cryopreservation and banking procedures for differing cell and tissue types.

Related News

MedTech

Vial Announces Strategic Partnership to Build CFR Part 11 Open Source e-Signature Platform with Documenso

PRNewswire | August 24, 2023

Vial, a global tech-driven CRO providing next-generation clinical trial management services, has announced a partnership with Documenso, an innovative open-source digital signing platform. The collaboration marks a significant step forward in revolutionizing document signing practices within the life science sector, providing a compelling alternative to traditional solutions like DocuSign. In an era where digital transformation is reshaping industries, Vial's partnership with Documenso is set to drive innovation in electronic document management, particularly in meeting the rigorous requirements of CFR Part 11 compliance. CFR Part 11 is a section of the Code of Federal Regulations (Title 21) established by the FDA. It lays out guidelines for electronic recordkeeping and signatures, ensuring data integrity and security in regulated sectors such as pharmaceuticals, biotechnology, and medical devices. "Vial's unwavering commitment to technological advancement has always been at the core of our mission to reimagine clinical trials. Our partnership with Documenso signifies an exciting leap towards innovation by addressing a critical need in the life science sector. Currently, very few providers offer solutions that align with the rigorous requirements of 21 CFR Part 11. We aim to collaborate with Documenso to develop one of the industry's first open-source document-signing products that meet the demands of 21 CFR Part 11. Together, we are poised to reshape how critical documents are managed and signed, driving us closer to a future where technology empowers every facet of scientific progress," said Simon Burns, CEO and Co-Founder of Vial. Vial's mission is to reimagine clinical trials to empower scientists to cure all human disease. Vial's driver for accomplishing this mission is applying a technology-forward approach. By deploying technology at every step, Vial is able to drive efficiencies in speed and cost savings for innovative biotech companies of all sizes. The Vial CRO distinguishes itself by leveraging its Vial Technology Platform, TrialOS, combining site start-up, visit data capture, and study analytics into one connected system. These best-in-class CRO services, combined with top vendor partnerships like Documenso, help accelerate the development of new therapies and devices for sponsors and patients. On the partnership, Timur, CEO, and Co-Founder of Documenso, commented, "Documenso is more than just a digital signing solution; it's a global commodity designed for longevity and scalability. We're excited to work alongside Vial in this endeavor, leveraging the power of Commercial Open Source (COSS) principles to provide a robust alternative to traditional solutions." About Vial Vial is a tech-first, next-generation CRO that promises faster and higher-quality execution of trials for less cost. The Vial Contract Research Organization (CRO) delivers on the promise of more efficient trials through its innovative technology platform that powers trials end-to-end from site startup to database lock. Vial's technology platform combines modern, intuitive eSource, EDC, and ePRO into one connected system, streamlining site processes and enabling considerable efficiencies. Vial operates across multiple Therapeutic Areas (Dermatology CRO, Ophthalmology CRO, Oncology CRO, Gastroenterology CRO, Neurology CRO, Cardiology CRO, Medical Device CRO, Rare Disease CRO, and Digital Therapeutics CRO). Vial is a San Francisco, California-based company with over 100+ employees. About Documenso Documenso is a groundbreaking open-source digital signing platform and alternative to traditional solutions like DocuSign. With a strong emphasis on customization and scalability, Documenso seamlessly integrates into business operations, offering extensive options for adaptation and an open API. Documenso was built for longevity and scale by embracing the capital efficiency and inclusiveness of the Commercial Open Source (COSS) movement. Documenso aims to create a global standard for digital signing that prioritizes inclusiveness and innovation.

Read More

MedTech, Medical

NanoString Platforms Advance Groundbreaking Studies of Immune Response in Pig-to-Human Organ Transplants

Businesswire | August 22, 2023

NanoString Technologies, Inc. a leading provider of life science tools for discovery and translational research, The seminal research led by Alexander Loupy, MD, Ph.D., in cooperation with a global medical team, unravels the complex molecular characteristics of antibody-mediated rejection following the first and second-ever pig-to-human kidney transplants that occurred in 2021 at NYU Langone Transplant Institute. In an accompanying Lancet commentary, scientists praised the team “for laying the foundation for deeper assessment of xenoimmunology and establishing immunological research pathways to advance xenotransplantation.” They also commented on the importance of “state-of-the-art spatial techniques” to decipher transcriptional immune activation. “We gained vital data and, for the first time ever, we were able to see what is happening immunologically in defined regions of the tissue,” said Dr. Loupy. “This data, enabled by NanoString’s platforms and an Allo - Xeno gene expression repository, allowed us to understand both the similarities and the novel aspects underpinning organ rejection in xenograft transplantation compared to human organ transplantation. NanoString’s nCounter and GeoMx instruments harmonized to create a holistic view of the immune response.” Researchers from the Paris Institute for Transplantation and Organ Regeneration, University of Paris, France’s National Institute of Health and Medical Research contributed to the study. Xenotransplantation, the process of transplanting organs from animals to humans, is a crucial area of research dedicated to addressing the profound shortage of healthy human organs available for transplant patients. The groundbreaking experimental transplant surgeries performed by Dr. Robert Montgomery at NYU since 2021 involve patients in a state of brain death. Their families and ethical committees have consented to artificially maintain blood circulation during the transplants to advance scientific knowledge on xenotransplantation with the hope of offering more healthy organs for future patients. The research team, including co-first authors of The Lancet study, Dr. Valentin Goutaudier and Dr. Alessia Giarraputto characterized the human immune response to the porcine kidney using bulk tissue transcriptome profiling on the nCounter Analysis System. Scientists used the nCounter Human Organ Transplant Panel, a process NanoString developed with the Banff International Classification Consortium. It is used by nearly one hundred global research institutions. The panel was adapted to xenotransplants by using bioinformatics-based pig and human gene sequences with homologies alignment. This analysis revealed a molecular architecture of antibody-mediated rejection, including interferon-gamma response, endothelial activation, macrophage activation, and injury repair response in the xenografts. The GeoMx Digital Spatial Profiler was used next to isolate the immune response to specific regions of the kidney. The GeoMx Whole Transcriptome Assay revealed that antibody-mediated injury was mainly located in the glomeruli of xenografts, with significant enrichment of transcripts associated with monocytes, macrophages, neutrophils, and NK cells. Drs. Loupy and Montgomery say their findings represent a treasure trove of new information for optimizing genetically modified pig models that may be useful in developing more advanced immunosuppressive treatments for future recipients of xenografts. “An estimated 100,000 people are waiting for organ transplants in the United States. Thousands die on the wait list. Numbers like these drive us at NanoString to provide researchers with the tools they need to find innovative solutions to solve extraordinary medical challenges,” commented Brad Gray, President and CEO of NanoString. “We congratulate Dr. Loupy and his extended team on their findings and celebrate the on-going successful studies in humans.” About NanoString Technologies, Inc. NanoString Technologies, is a leader in spatial biology, offers an ecosystem of innovative discovery and translational research solutions, empowering our customers to map the universe of biology. The GeoMx® Digital Spatial Profiler is a flexible and consistent solution combining the power of whole tissue imaging with gene expression and protein data for spatial whole transcriptomics and proteomics. The CosMx™ Spatial Molecular Imager is a single-cell imaging platform powered by spatial multiomics enabling researchers to map single cells in their native environments to extract deep biological insights and novel discoveries from one experiment. The AtoMx™ Spatial Informatics Platform is a cloud-based informatics solution with advanced analytics and global collaboration capabilities, enabling powerful spatial biology insights anytime, anywhere. At the foundation of our research tools is our nCounter® Analysis System, which offers a secure way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision.

Read More

MedTech

Watchmaker Genomics Announces Co-Exclusive License to Disruptive DNA Methylation Technology and Strategic Supply Agreements with Exact Sciences

businesswire | August 31, 2023

Watchmaker Genomics, a supplier of innovative products for molecular analysis, today announced a multi-year, co-exclusive agreement with Exact Sciences Corporation, a leading provider of cancer screening and diagnostic tests, to develop and commercialize the breakthrough DNA methylation analysis technology, TET-assisted pyridine borane sequencing (TAPS). Watchmaker will apply its expertise in engineering DNA-modifying enzymes to further improve the TAPS chemistry, ultimately enabling advanced applications, including cancer screening and minimal residual disease (MRD) testing. Under the licensing agreement, Watchmaker may develop and commercialize the TAPS technology under its own brand. DNA methylation patterns offer dynamic and rich insights into the status of both healthy and diseased tissue. These signatures are stable, relatively abundant, and often measurable in the blood, making them promising biomarkers in minimally invasive liquid biopsies. TAPS has the potential to dramatically improve DNA methylation analysis accuracy by enabling a direct readout of cytosine methylation with less template damage and noise when compared to existing methods.1 "Exact Sciences is a leader in cancer screening, and this agreement is a great fit with Watchmaker’s core competencies in next-generation sequencing and genomics applications," said Brian Kudlow, Ph.D., Chief Scientific Officer at Watchmaker Genomics. "It aligns with our belief that multimodal genomic and epigenomic assays represent the frontier of numerous liquid biopsy applications, including early cancer detection." In addition to the development and licensing agreement, the companies have entered into a long-term strategic supply agreement. Under its terms, Watchmaker will provide Exact Sciences with access to its portfolio of best-in-class sequencing reagents and precision enzymes. These products have the potential to enhance the performance of Exact Sciences’ tests while significantly reducing associated costs. “Our company’s mission is to develop and broadly commercialize tools that improve the efficiency of capturing and interpreting the biological information required for many advanced genetic testing applications,” said Trey Foskett, CEO of Watchmaker Genomics. “This arrangement provides us with an exciting opportunity to accelerate the development and commercialization of a game-changing technology to the benefit of the broader research and clinical genomics markets.” About Watchmaker Genomics Watchmaker Genomics applies advanced enzymology to enable breakthrough applications for the reading, writing, and editing of DNA and RNA. The company combines domain expertise in protein engineering with large-scale enzyme manufacturing to address the demanding quality, performance, and scale requirements of high-growth clinical genomics applications. Watchmaker's product portfolio includes enzymes and kits for next-generation sequencing, synthetic biology, and molecular diagnostics. A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis.

Read More

MedTech

Vial Announces Strategic Partnership to Build CFR Part 11 Open Source e-Signature Platform with Documenso

PRNewswire | August 24, 2023

Vial, a global tech-driven CRO providing next-generation clinical trial management services, has announced a partnership with Documenso, an innovative open-source digital signing platform. The collaboration marks a significant step forward in revolutionizing document signing practices within the life science sector, providing a compelling alternative to traditional solutions like DocuSign. In an era where digital transformation is reshaping industries, Vial's partnership with Documenso is set to drive innovation in electronic document management, particularly in meeting the rigorous requirements of CFR Part 11 compliance. CFR Part 11 is a section of the Code of Federal Regulations (Title 21) established by the FDA. It lays out guidelines for electronic recordkeeping and signatures, ensuring data integrity and security in regulated sectors such as pharmaceuticals, biotechnology, and medical devices. "Vial's unwavering commitment to technological advancement has always been at the core of our mission to reimagine clinical trials. Our partnership with Documenso signifies an exciting leap towards innovation by addressing a critical need in the life science sector. Currently, very few providers offer solutions that align with the rigorous requirements of 21 CFR Part 11. We aim to collaborate with Documenso to develop one of the industry's first open-source document-signing products that meet the demands of 21 CFR Part 11. Together, we are poised to reshape how critical documents are managed and signed, driving us closer to a future where technology empowers every facet of scientific progress," said Simon Burns, CEO and Co-Founder of Vial. Vial's mission is to reimagine clinical trials to empower scientists to cure all human disease. Vial's driver for accomplishing this mission is applying a technology-forward approach. By deploying technology at every step, Vial is able to drive efficiencies in speed and cost savings for innovative biotech companies of all sizes. The Vial CRO distinguishes itself by leveraging its Vial Technology Platform, TrialOS, combining site start-up, visit data capture, and study analytics into one connected system. These best-in-class CRO services, combined with top vendor partnerships like Documenso, help accelerate the development of new therapies and devices for sponsors and patients. On the partnership, Timur, CEO, and Co-Founder of Documenso, commented, "Documenso is more than just a digital signing solution; it's a global commodity designed for longevity and scalability. We're excited to work alongside Vial in this endeavor, leveraging the power of Commercial Open Source (COSS) principles to provide a robust alternative to traditional solutions." About Vial Vial is a tech-first, next-generation CRO that promises faster and higher-quality execution of trials for less cost. The Vial Contract Research Organization (CRO) delivers on the promise of more efficient trials through its innovative technology platform that powers trials end-to-end from site startup to database lock. Vial's technology platform combines modern, intuitive eSource, EDC, and ePRO into one connected system, streamlining site processes and enabling considerable efficiencies. Vial operates across multiple Therapeutic Areas (Dermatology CRO, Ophthalmology CRO, Oncology CRO, Gastroenterology CRO, Neurology CRO, Cardiology CRO, Medical Device CRO, Rare Disease CRO, and Digital Therapeutics CRO). Vial is a San Francisco, California-based company with over 100+ employees. About Documenso Documenso is a groundbreaking open-source digital signing platform and alternative to traditional solutions like DocuSign. With a strong emphasis on customization and scalability, Documenso seamlessly integrates into business operations, offering extensive options for adaptation and an open API. Documenso was built for longevity and scale by embracing the capital efficiency and inclusiveness of the Commercial Open Source (COSS) movement. Documenso aims to create a global standard for digital signing that prioritizes inclusiveness and innovation.

Read More

MedTech, Medical

NanoString Platforms Advance Groundbreaking Studies of Immune Response in Pig-to-Human Organ Transplants

Businesswire | August 22, 2023

NanoString Technologies, Inc. a leading provider of life science tools for discovery and translational research, The seminal research led by Alexander Loupy, MD, Ph.D., in cooperation with a global medical team, unravels the complex molecular characteristics of antibody-mediated rejection following the first and second-ever pig-to-human kidney transplants that occurred in 2021 at NYU Langone Transplant Institute. In an accompanying Lancet commentary, scientists praised the team “for laying the foundation for deeper assessment of xenoimmunology and establishing immunological research pathways to advance xenotransplantation.” They also commented on the importance of “state-of-the-art spatial techniques” to decipher transcriptional immune activation. “We gained vital data and, for the first time ever, we were able to see what is happening immunologically in defined regions of the tissue,” said Dr. Loupy. “This data, enabled by NanoString’s platforms and an Allo - Xeno gene expression repository, allowed us to understand both the similarities and the novel aspects underpinning organ rejection in xenograft transplantation compared to human organ transplantation. NanoString’s nCounter and GeoMx instruments harmonized to create a holistic view of the immune response.” Researchers from the Paris Institute for Transplantation and Organ Regeneration, University of Paris, France’s National Institute of Health and Medical Research contributed to the study. Xenotransplantation, the process of transplanting organs from animals to humans, is a crucial area of research dedicated to addressing the profound shortage of healthy human organs available for transplant patients. The groundbreaking experimental transplant surgeries performed by Dr. Robert Montgomery at NYU since 2021 involve patients in a state of brain death. Their families and ethical committees have consented to artificially maintain blood circulation during the transplants to advance scientific knowledge on xenotransplantation with the hope of offering more healthy organs for future patients. The research team, including co-first authors of The Lancet study, Dr. Valentin Goutaudier and Dr. Alessia Giarraputto characterized the human immune response to the porcine kidney using bulk tissue transcriptome profiling on the nCounter Analysis System. Scientists used the nCounter Human Organ Transplant Panel, a process NanoString developed with the Banff International Classification Consortium. It is used by nearly one hundred global research institutions. The panel was adapted to xenotransplants by using bioinformatics-based pig and human gene sequences with homologies alignment. This analysis revealed a molecular architecture of antibody-mediated rejection, including interferon-gamma response, endothelial activation, macrophage activation, and injury repair response in the xenografts. The GeoMx Digital Spatial Profiler was used next to isolate the immune response to specific regions of the kidney. The GeoMx Whole Transcriptome Assay revealed that antibody-mediated injury was mainly located in the glomeruli of xenografts, with significant enrichment of transcripts associated with monocytes, macrophages, neutrophils, and NK cells. Drs. Loupy and Montgomery say their findings represent a treasure trove of new information for optimizing genetically modified pig models that may be useful in developing more advanced immunosuppressive treatments for future recipients of xenografts. “An estimated 100,000 people are waiting for organ transplants in the United States. Thousands die on the wait list. Numbers like these drive us at NanoString to provide researchers with the tools they need to find innovative solutions to solve extraordinary medical challenges,” commented Brad Gray, President and CEO of NanoString. “We congratulate Dr. Loupy and his extended team on their findings and celebrate the on-going successful studies in humans.” About NanoString Technologies, Inc. NanoString Technologies, is a leader in spatial biology, offers an ecosystem of innovative discovery and translational research solutions, empowering our customers to map the universe of biology. The GeoMx® Digital Spatial Profiler is a flexible and consistent solution combining the power of whole tissue imaging with gene expression and protein data for spatial whole transcriptomics and proteomics. The CosMx™ Spatial Molecular Imager is a single-cell imaging platform powered by spatial multiomics enabling researchers to map single cells in their native environments to extract deep biological insights and novel discoveries from one experiment. The AtoMx™ Spatial Informatics Platform is a cloud-based informatics solution with advanced analytics and global collaboration capabilities, enabling powerful spatial biology insights anytime, anywhere. At the foundation of our research tools is our nCounter® Analysis System, which offers a secure way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision.

Read More

MedTech

Watchmaker Genomics Announces Co-Exclusive License to Disruptive DNA Methylation Technology and Strategic Supply Agreements with Exact Sciences

businesswire | August 31, 2023

Watchmaker Genomics, a supplier of innovative products for molecular analysis, today announced a multi-year, co-exclusive agreement with Exact Sciences Corporation, a leading provider of cancer screening and diagnostic tests, to develop and commercialize the breakthrough DNA methylation analysis technology, TET-assisted pyridine borane sequencing (TAPS). Watchmaker will apply its expertise in engineering DNA-modifying enzymes to further improve the TAPS chemistry, ultimately enabling advanced applications, including cancer screening and minimal residual disease (MRD) testing. Under the licensing agreement, Watchmaker may develop and commercialize the TAPS technology under its own brand. DNA methylation patterns offer dynamic and rich insights into the status of both healthy and diseased tissue. These signatures are stable, relatively abundant, and often measurable in the blood, making them promising biomarkers in minimally invasive liquid biopsies. TAPS has the potential to dramatically improve DNA methylation analysis accuracy by enabling a direct readout of cytosine methylation with less template damage and noise when compared to existing methods.1 "Exact Sciences is a leader in cancer screening, and this agreement is a great fit with Watchmaker’s core competencies in next-generation sequencing and genomics applications," said Brian Kudlow, Ph.D., Chief Scientific Officer at Watchmaker Genomics. "It aligns with our belief that multimodal genomic and epigenomic assays represent the frontier of numerous liquid biopsy applications, including early cancer detection." In addition to the development and licensing agreement, the companies have entered into a long-term strategic supply agreement. Under its terms, Watchmaker will provide Exact Sciences with access to its portfolio of best-in-class sequencing reagents and precision enzymes. These products have the potential to enhance the performance of Exact Sciences’ tests while significantly reducing associated costs. “Our company’s mission is to develop and broadly commercialize tools that improve the efficiency of capturing and interpreting the biological information required for many advanced genetic testing applications,” said Trey Foskett, CEO of Watchmaker Genomics. “This arrangement provides us with an exciting opportunity to accelerate the development and commercialization of a game-changing technology to the benefit of the broader research and clinical genomics markets.” About Watchmaker Genomics Watchmaker Genomics applies advanced enzymology to enable breakthrough applications for the reading, writing, and editing of DNA and RNA. The company combines domain expertise in protein engineering with large-scale enzyme manufacturing to address the demanding quality, performance, and scale requirements of high-growth clinical genomics applications. Watchmaker's product portfolio includes enzymes and kits for next-generation sequencing, synthetic biology, and molecular diagnostics. A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis.

Read More

Events